Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease

Gastroenterology

Volumn 149, Issue 3, 2015, Pages 649-659

  Charlton, Michael ^a   Everson, Gregory T ^b   Flamm, Steven L ^c   Kumar, Princy ^d   Landis, Charles ^e   Brown, Robert S ^f   Fried, Michael W ^g   Terrault, Norah A ^h   O'Leary, Jacqueline G ⁱ   Vargas, Hugo E ^j   Kuo, Alexander ^k   Schiff, Eugene ^l   Sulkowski, Mark S ^m   Gilroy, Richard ⁿ   Watt, Kymberly D ^o   Brown, Kimberly ^p   Kwo, Paul ^q   Pungpapong, Surakit ^r   Korenblat, Kevin M ^s   Muir, Andrew J ^t   Teperman, Lewis ^u   Fontana, Robert J ^v   Denning, Jill ^w   Arterburn, Sarah ^w   Dvory Sobol, Hadas ^w   Brandt Sarif, Theo ^w   Pang, Phillip S ^w   McHutchison, John G ^w   Reddy, K Rajender ^x   Afdhal, Nezam ^y   more..

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^j MAYO CLINIC   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF MIAMI   (United States)

^m JOHNS HOPKINS UNIVERSITY   (United States)

ⁿ UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^o MAYO CLINIC   (United States)

^p HENRY FORD HEALTH SYSTEM   (United States)

^q INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r MAYO CLINIC   (United States)

^s WASHINGTON UNIVERSITY   (United States)

^t DUKE UNIVERSITY   (United States)

^u NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^v UNIVERSITY OF MICHIGAN   (United States)

^w GILEAD SCIENCES   (United States)

^x UNIVERSITY OF PENNSYLVANIA   (United States)

^y BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

Decompensated Cirrhosis; Fibrosing Cholestatic Hepatitis; Hepatitis C Virus Infection; Liver Transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LEDIPASVIR; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; DRUG COMBINATION; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ACUTE KIDNEY FAILURE; ADULT; AORTA DISSECTION; ARTICLE; CHOLESTATIC HEPATITIS; COHORT ANALYSIS; CONTROLLED STUDY; CONVULSION; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEMOPERITONEUM; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; HYDROTHORAX; HYPOTENSION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODERATE HEPATIC IMPAIRMENT; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEVERE HEPATIC IMPAIRMENT; SHOCK; THORAX PAIN; TREATMENT DURATION; VOMITING; ANALOGS AND DERIVATIVES; CHOLESTASIS, INTRAHEPATIC; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DISEASE COURSE; DRUG COMBINATION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VIROLOGY;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CHOLESTASIS, INTRAHEPATIC; DISEASE PROGRESSION; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; URIDINE MONOPHOSPHATE;

EID: 84938953785     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.05.010     Document Type: Article

References (26)

1. S.A. Fink, and I.M. Jacobson Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis Nat Rev Gastroenterol Hepatol 8 2011 285 295
2. P.A. Berry, and S.J. Thomson The patient presenting with decompensated cirrhosis Acute Med 12 2013 232 238
3. W.R. Kim, J.M. Smith, M.A. Skeans, and et al. OPTN/SRTR 2012 annual data report: liver Am J Transplant 14 Suppl 1 2014 69 96
4. R. Adam, P. McMaster, J.G. O'Grady, and et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry Liver Transpl 9 2003 1231 1243
5. M. Charlton, K. Ruppert, S.H. Belle, and et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database Liver Transpl 10 2004 1120 1130
6. M. Berenguer, M. Prieto, J.M. Rayon, and et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation Hepatology 32 2000 852 858
7. L.M. Forman, J.D. Lewis, J.A. Berlin, and et al. The association between hepatitis C infection and survival after orthotopic liver transplantation Gastroenterology 122 2002 889 896
8. Sovaldi (sofosbuvir) tablets; US prescribing information 2013 Gilead Sciences Foster City, CA Available from: https://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi-pi.pdf
9. M.P. Curry, X. Forns, R.T. Chung, and et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study Gastroenterology 148 2015 100 107
10. M. Charlton, E. Gane, M.P. Manns, and et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation Gastroenterology 148 2015 108 117
11. X. Forns, M. Charlton, J. Denning, and et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation Hepatology 61 2015 1485 1494
12. Harvoni (ledipasvir and sofosbuvir) tablets: US prescribing information 2014 Gilead Sciences Foster City, CA Available from: http://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni-pi.pdf
13. M. Bourlière, J.-P. Bronowicki, V. de Ledinghen, and et al. Ledipasvir and sofosbuvir for 12 weeks with ribavirin or for 24 weeks alone in patients with genotype 1 HCV infection and cirrhosis in whom prior protease inhibitor therapy failed (SIRIUS): a randomized, double-blind, phase 2 trial Lancet Infect Dis 15 2015 397 404
14. E. Schiff, C.L. Lai, S. Hadziyannis, and et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results Liver Transpl 13 2007 349 360
15. E.R. Schiff, C.L. Lai, S. Hadziyannis, and et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients Hepatology 38 2003 1419 1427
16. C. Delabaudière, L. Lavayssière, G. Dörr, and et al. Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation Transpl Int 28 2015 255 258
17. P. Borentain, P. Colson, C. Dhiver, and et al. Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in HIV-HCV coinfected patient Antivir Ther 20 2015 252 356
18. B. Kim, A. Trivedi, S.N. Thung, and et al. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation Semin Liver Dis 34 2014 108 112
19. N. Al Nahdi, J.A. Ford, E.D. Greanya, and et al. First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder Ann Hepatol 12 2013 156 160
20. N. Afdhal, S. Zeuzem, P. Kwo, and et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
21. N. Afdhal, K.R. Reddy, D.R. Nelson, and et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 2014 1483 1493
22. P.Y. Kwo, P.S. Mantry, E. Coakley, and et al. An interferon-free antiviral regimen for HCV after liver transplantation N Engl J Med 371 2014 2375 2382
23. J.F. Trotter, J.C. Osborne, M. Heller, and et al. Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients Aliment Pharmacol Ther 22 2005 37 44
24. T.R. Morgan, M.G. Ghany, H.Y. Kim, and et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C Hepatology 52 2010 833 844
25. B.J. Veldt, E.J. Heathcote, H. Wedemeyer, and et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis Ann Intern Med 147 2007 677 684
26. R. Wiesner, E. Edwards, R. Freeman, and et al. Model for end-stage liver disease (MELD) and allocation of donor livers Gastroenterology 124 2003 91 96